Investor Presentaiton

Investor presentation ADA 2019 Slide 33 Oral semaglutide filed in the USA, the EU and Canada, and OzempicⓇ CV risk reduction indication filed in the USA Expected timelines for the FDA review Q1 2019 | Q2 2019 | Q3 2019 | Q4 2019 | Q1 2020 Oral semaglutide Expected review time: 6 months Oral semaglutide (CV indication) Expected review time: 10 months Ozempic® (CV indication) Expected review time: 10 months Oral semaglutide filed in key markets Three FDA filings: . NDA for oral semaglutide for glycaemic control . NDA for oral semaglutide CV indication . SNDA for Ozempic® CV indication Regulatory filing in the EU for oral semaglutide for type 2 diabetes treatment Regulatory filing in Canada for oral semaglutide for type 2 diabetes treatment CV: Cardiovascular; FDA: the US Food and Drug Administration; Q: Quarter; NDA: New Drug Application; SNDA: Supplementary New Drug Application novo nordisk

View entire presentation